28081-52-9

Usage

Uses

Used in Pharmaceutical Applications:
(3-METHYL-4-OXO-3,4-DIHYDRO-PHTHALAZIN-1-YL)-ACETIC ACID is used as a potential pharmaceutical agent due to its unique structure and properties. Its carboxylic acid group may allow for interactions with various biological targets, offering potential therapeutic benefits. However, further studies are needed to fully understand its effects and optimize its use in drug development.
Used in Research and Development:
In the field of chemical research, (3-METHYL-4-OXO-3,4-DIHYDRO-PHTHALAZIN-1-YL)-ACETIC ACID serves as a valuable compound for studying the properties and behavior of phthalazine derivatives. Its synthesis and modification can provide insights into the development of new chemical entities with potential applications in various industries.
Safety Considerations:
When working with (3-METHYL-4-OXO-3,4-DIHYDRO-PHTHALAZIN-1-YL)-ACETIC ACID in a laboratory setting, it is crucial to follow safety guidelines and handle the compound with care. Proper protective equipment, such as gloves and eyewear, should be worn, and the compound should be stored and disposed of according to established protocols to ensure the safety of researchers and the environment.

InChI:InChI=1/C11H10N2O3/c1-13-11(16)8-5-3-2-4-7(8)9(12-13)6-10(14)15/h2-5H,6H2,1H3,(H,14,15)/p-1

Upstream product

• 85-44-9 phthalic anhydride 
• 57691-07-3 ethyl [(E)-3-oxo-1,3-dihydroisobenzofuran-1-ylidene]acetate 
• 356790-62-0 ethyl 2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetate 
• 25947-13-1 ethyl 1,2-dihydro-1-oxophthalazin-4-ylacetate 
• 13141-32-7 ethyl 2-(3-oxo-1,3-dihydro-1-isobenzofuranyliden)acetate 

Downstream Products

• 431930-94-8 C₁₈H₁₇N₃O₃ 
• 429653-39-4 C₁₈H₁₇N₃O₃ 
• 1245749-73-8 C₁₈H₁₇N₃O₃ 
• 1004009-95-3 C₁₉H₁₉N₃O₃ 
• 1001516-81-9 C₁₈H₁₄F₃N₃O₃ 
• 351066-18-7 C₁₈H₁₇N₃O₂ 
• 874584-98-2 C₂₀H₂₁N₃O₂ 
• 434292-87-2 C₁₉H₁₉N₃O₃ 
• 421570-14-1 C₁₇H₁₄ClN₃O₂ 
• 510760-36-8 C₁₇H₁₄BrN₃O₂ 
• 1004009-33-9 C₁₇H₁₄FN₃O₂ 
• 1325755-24-5 C₁₈H₁₄N₄O₂ 
• 434293-11-5 C₁₈H₁₄F₃N₃O₂ 
• 1286127-58-9 C₁₈H₁₇N₃O₄S 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS

Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound selectively inhibits a parasitic IMPDH versus a host IMPDH. Also disclosed are pharmaceutical compositions comprising one or more compounds of the invention. Related methods of treating various parasitic and bacterial infections in mammals are disclosed. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.

Discovery of thiazolyl-phthalazinone acetamides as potent glucose uptake activators via high-throughput screening

With the aim to discover orally active small molecules that stimulate glucose uptake, high throughput screening of a library of 5000 drug-like compounds was conducted in differentiated skeletal muscle cells in presence of insulin. N-Substituted phthalazinone acetamide was identified as a potential glucose uptake modulator. Several novel derivatives were synthesized to establish structure activity relationships. Identified lead thiazolyl- phthalazinone acetamide (7114863) increased glucose uptake (EC50 of 0.07 ± 0.02 μM) in differentiated skeletal muscle cells in presence of insulin. Furthermore, 7114863 was superior to rosiglitazone under similar experimental conditions without inducing PPAR-γ agonist activity thus making it a very interesting scaffold.

Phthalazinone inhibitors of inosine-5′-monophosphate dehydrogenase from Cryptosporidium parvum

Cryptosporidium parvum (Cp) is a potential biowarfare agent and major cause of diarrhea and malnutrition. This protozoan parasite relies on inosine 5′-monophosphate dehydrogenase (IMPDH) for the production of guanine nucleotides. A CpIMPDH-selective N-aryl-3,4-dihydro-3-methyl-4-oxo-1- phthalazineacetamide inhibitor was previously identified in a high throughput screening campaign. Herein we report a structure-activity relationship study for the phthalazinone-based series that resulted in the discovery of benzofuranamide analogs that exhibit low nanomolar inhibition of CpIMPDH. In addition, the antiparasitic activity of select analogs in a Toxoplasma gondii model of C. parvum infection is also presented.